These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 18496562

  • 1. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 2. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR.
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [Abstract] [Full Text] [Related]

  • 3. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 4. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O, Levine RL.
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [Abstract] [Full Text] [Related]

  • 5. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A.
    Med Clin (Barc); 2012 Oct 13; 139(9):373-8. PubMed ID: 22743278
    [Abstract] [Full Text] [Related]

  • 6. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 13; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 7. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.
    APMIS; 2011 Aug 13; 119(8):498-504. PubMed ID: 21749449
    [Abstract] [Full Text] [Related]

  • 8. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I, Vainchenker W.
    Clin Lymphoma Myeloma; 2009 Aug 13; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [Abstract] [Full Text] [Related]

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 10. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 06; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 11. Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms.
    Yönal-Hindilerden İ, Şahin E, Hindilerden F, Dağlar-Aday A, Nalçacı M.
    Turk J Haematol; 2023 Aug 31; 40(3):174-182. PubMed ID: 37584526
    [Abstract] [Full Text] [Related]

  • 12. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Chen P, Ouyang J, Liang J, Yu X, Huang B.
    Clin Lab; 2016 Aug 01; 62(8):1477-1481. PubMed ID: 28164603
    [Abstract] [Full Text] [Related]

  • 13. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Aug 01; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 14. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 01; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 15. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A, Angona A, Martínez-Avilés L, Bellosillo B, Besses C.
    Leuk Res; 2012 Mar 01; 36(3):324-6. PubMed ID: 22001278
    [Abstract] [Full Text] [Related]

  • 16. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul 01; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 17. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb 01; 19(1):239-43. PubMed ID: 21362261
    [Abstract] [Full Text] [Related]

  • 18. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F.
    Ann Hematol; 2014 May 01; 93(5):797-802. PubMed ID: 24337516
    [Abstract] [Full Text] [Related]

  • 19. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.
    Int J Hematol; 2018 Jun 01; 107(6):673-680. PubMed ID: 29464483
    [Abstract] [Full Text] [Related]

  • 20. Genotype-phenotype interactions in the myeloproliferative neoplasms.
    Godfrey AL, Green AR.
    Hematol Oncol Clin North Am; 2012 Oct 01; 26(5):993-1015. PubMed ID: 23009934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.